SCHEMBL5403130

SCHEMBL5403130

CC(C)COc1ccccc1CN1CCC2(CC1)CCN(C(=O)Cc1ccc(C(C)C)cc1)C2

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CCR8 P51685 3/20 0.59
KCNH2 Q12809 3/20 0.59
CYP2D6 P10635 8/20 0.47
TSHR P16473 2/20 0.47
KDM4E B2RXH2 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD11B1 P28845 2/20 0.44
CYP2C19 P33261 1/20 0.44
GHSR Q92847 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5428127 0.95 CCR8 (0.54) CCR8KCNH2CYP2D6TSHRKDM4E
SCHEMBL5392143 0.94 CCR8 (0.57) CCR8KCNH2CYP2D6TSHRKDM4E
SCHEMBL5405353 0.93 CCR8 (0.59) CCR8KCNH2CYP2D6TSHRKDM4E
SCHEMBL5399247 0.92 CCR8 (0.60) CCR8KCNH2CYP2D6TSHRKDM4E
Trifluoroacetic Acid SCHEMBL5437579 0.90 CCR8 (0.52) CCR8KCNH2CYP2D6TSHRKDM4E
SCHEMBL5395055 0.89 CCR8 (0.57) CCR8KCNH2CYP2D6TSHRKDM4E
SCHEMBL5389952 0.89 CCR8 (0.72) CCR8KCNH2CYP2D6TSHRKDM4E
SCHEMBL5396042 0.89 CCR8 (0.56) CCR8KCNH2CYP2D6TSHRKDM4E
SCHEMBL5391243 0.88 CCR8 (0.58) CCR8KCNH2CYP2D6TSHRKDM4E
Trifluoroacetic Acid SCHEMBL5428442 0.88 CCR8 (0.54) CCR8KCNH2CYP2D6TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases ASTRAZENECA AB (SE) 2007-10-25 US claimed
JP-2007509141-A 2007-04-12 JP claimed
EP-1678178-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2006-07-12 EP claimed
WO-2005040167-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2005-05-06 WO claimed
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases ASTRAZENECA AB (SE) 2007-10-25 US disclosed
EP-1678178-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES AstraZeneca AB (SE) 2006-07-12 EP disclosed
WO-2005040167-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249648-A1 Novel Diazaspiroalkanes and Their Use for Treatment of Ccr8 Mediated Diseases CCR8, CCR1, CCR10 CCR8 1/4885KCNH2 2793/4885CYP2D6 1764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.